PB0103 - Evaluation of Changes in Antiphospholipid Antibody Titers Following Vaccination with SARS-CoV-2 mRNA in Patients with Autoimmune Diseases

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Mitsutaka Yasuda, MD

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan

Co-Author(s)

YF

Yuichiro Fujieda

Assistant Professor
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
KS

Kodai Sakiyama

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
MT

Maria Tada

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
NT

Naohisa Tsuchida

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
KN

Kokoro Nishino

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
HM

Haruka Moriya

Senior Resident
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
MK

Michihito Kono

Assistant Professor
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
MK

Masaru Kato

Lecturer
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
OA

Olga Amengual

Lecturer
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan
TA

Tatsuya Atsumi

Professor
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Sapporo, Hokkaido, Japan

Background: Severe coronavirus disease 2019 (COVID-19) is characterized by a hypercoagulable state and antiphospholipid antibodies (aPLs) are detected in some cases. Since elevation of aPLs could be the risk of thrombosis.

Aims: We aim to evaluate the change of aPLs’ titers and the potential risk of thrombosis after vaccination against of SARS-CoV-2 in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE).

Methods: This study comprised patients with primary APS (PAPS), APS associated with systemic lupus erythematosus (SLE/APS), SLE aPL carriers (SLE/aPL+), and SLE without aPLs (SLE/aPL-) who received the first and second dose of COVID-19 mRNA vaccine. Serum anti-cardiolipin antibody (aCLIgG, IgM), anti-2GPI antibody (a2GPI IgG, IgM) detected by chemiluminescent immunoassay (CLIA), and anti-phosphatidylserine/prothrombin complex antibody (aPS/PT IgG, IgM) tested an in-house enzyme-linked immunosorbent assay (ELISA) were evaluated before and 4 weeks after vaccination.. The cut-off values were > 20.0 U/mL for aCL（IgG, IgM）/a2GPI （IgG, IgM）, >1.2 U/mL for aPS/PT IgG and >5.2 U/mL for aPS/PT IgM. A titer elevation of more than 10% after vaccination was defined as a significant elevation.

Results: A total of 32 patients were enrolled; 4 PAPS, 9 SLE-APS, 3 SLE-aPL+, and 16 SLE-aPL-.
Among aPL+ patients ( n=16), there was no significant elevation of aPLs titers after vaccination (Table). Four weeks after vaccination, aPLs positivity was detected in three patients in the SLE/aPL- group ( aCL IgG, 2 patients, a2GPI IgG 1 patients). In the SLE/aPL+ group, two SLE/APS patients had positive a2GPI IgG. No acute thrombotic events were observed during the observation period.

Conclusion(s): There was no significant change in aPL titers after vaccination in patients with APS and/or SLE. None of the patients developed a thrombotic event after vaccination.